On 2014, the French government decided to provide the company with a 3 years accreditation for Crédit d’Impôt Recherche (CIR). Although, most of GalChimia’s work is R&D for third parties, covering the whole range of chemical development needed in the development of new drugs, the company has invested in new technologies and developing new synthetic methodologies, looking always to offer the best service to its customers.
Recently, GalChimia has achieved the renovation of the accreditation for Crédit d’Impôt Recherche (CIR) by the French government, for the years 2017, 2018 and 2019. The evaluation were related to our participation to the project Neogalfarma. The high R&D value of this project based on the development of new immunotherapy convinced the French administration about the research activities performed at GalChimia.
As reminder, the conditions are that 30% of the R&D expenses, related to human and material resources spent internally but also the expenses sub-contracted to academic centers or specific companies accredited by the French government can be financed with the CIR up to a limit defined by the internal capabilities of the companies or a maximum of €100 Millions.
Considered nowadays as the best tax incentive system for research in Europe, the CIR is a tax tool, that works as a real growth lever for any company choosing to invest in basic research, applied research and experimental development. These provisions encourage private investment in R&D, stimulate the creation of R&D companies and attract foreign company research centers.